Molecular and structural insights into SARS-CoV-2 evolution: from BA.2 to XBB subvariants
- PMID: 39283095
- PMCID: PMC11481514
- DOI: 10.1128/mbio.03220-23
Molecular and structural insights into SARS-CoV-2 evolution: from BA.2 to XBB subvariants
Abstract
Due to the incessant emergence of various SARS-CoV-2 variants with enhanced fitness in the human population, controlling the COVID-19 pandemic has been challenging. Understanding how the virus enhances its fitness during a pandemic could offer valuable insights for more effective control of viral epidemics. In this manuscript, we review the evolution of SARS-CoV-2 from early 2022 to the end of 2023-from Omicron BA.2 to XBB descendants. Focusing on viral evolution during this period, we provide concrete examples that SARS-CoV-2 has increased its fitness by enhancing several functions of the spike (S) protein, including its binding affinity to the ACE2 receptor and its ability to evade humoral immunity. Furthermore, we explore how specific mutations modify these functions of the S protein through structural alterations. This review provides evolutionary, molecular, and structural insights into how SARS-CoV-2 has increased its fitness and repeatedly caused epidemic surges during the pandemic.
Keywords: Omicron; SARS-CoV-2; evolution; molecular phylogenetic; spike; structural biology.
Conflict of interest statement
J.I. has consulting fees and honoraria for lectures from Takeda Pharmaceutical Co. Ltd. K.S. has consulting fees from Moderna Japan Co., Ltd., and Takeda Pharmaceutical Co. Ltd. and honoraria for lectures from Gilead Sciences, Inc., Moderna Japan Co., Ltd., and Shionogi & Co., Ltd. The other authors declare no competing interests. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the paper have been disclosed.
Figures
References
-
- Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, Peacock SJ, Barclay WS, de Silva TI, Towers GJ, Robertson DL, COVID-19 Genomics UK Consortium . 2023. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol 21:162–177. doi:10.1038/s41579-022-00841-7 - DOI - PMC - PubMed
-
- Ferreira I, Kemp SA, Datir R, Saito A, Meng B, Rakshit P, Takaori-Kondo A, Kosugi Y, Uriu K, Kimura I, Shirakawa K, Abdullahi A, Agarwal A, Ozono S, Tokunaga K, Sato K, Gupta RK, CITIID-NIHR BioResource COVID-19 Collaboration, Indian SARS-CoV-2 Genomics Consortium, Genotype to Phenotype Japan (G2P-Japan) Consortium . 2021. SARS-CoV-2 B.1.617 mutations L452R and E484Q are not synergistic for antibody evasion. J Infect Dis 224:989–994. doi:10.1093/infdis/jiab368 - DOI - PMC - PubMed
-
- Uriu K, Kimura I, Shirakawa K, Takaori-Kondo A, Nakada T-A, Kaneda A, Nakagawa S, Sato K, Genotype to Phenotype Japan (G2P-Japan) Consortium . 2021. Neutralization of the SARS-CoV-2 mu variant by convalescent and vaccine serum. N Engl J Med 385:2397–2399. doi:10.1056/NEJMc2114706 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
- JP24jf0126002/AMED | ASPIRE Program
- JP243fa627001/AMED | SCARDA Japan Initiative for World-leading Vaccine Research and Development Centers "UTOPIA"
- JP243fa727002/AMED | SCARDA Program on R&D of new generation vaccine including new modality application
- JP223fa627009/AMED | SCARDA Kyoto University Immunomonitoring Center (KIC)
- JP223fa627005/AMED | SCARDA Hokkaido University Institute for Vaccine Research and Development (HU-IVReD)
- JP17am0101093 and JP22ama121037/AMED | BINDS
- JP21fk0108463 and JP22gm1810004/AMED | CREST
- JP24fk0108690/AMED | Research Program on Emerging and Re-emerging Infectious Diseases
- JP22fk0108572 and JP24wm0225025/AMED | Research Program on Emerging and Re-emerging Infectious Diseases
- JPMJPR22R1/JST | PRESTO
- JP23K20041/JSPS | KAKENHI Fund for the Promotion of Joint International Research (International Leading Research)
- JP23K14526/JSPS | KAKENHI Grant-in-Aid for Early-Career Scientists
- JP24H00607/JSPS | KAKENHI Grant-in-Aid for Scientific Research A
- JP20K20596/JSPS | KAKENHI Grant-in-Aid for Challenging Research (Exploratory)
- JP20H05873/JSPS | KAKENHI Grant-in-Aid for The Scientific Research on Innovative Areas and International Group
- JPJSCCA20240006/JSPS | Core-to-Core Program (A. Advanced Research Networks)
- NA/Mitsubishi UFJ Financial Group, Inc. Vaccine Development Grant
- NA/International Joint Research Project of the Institute of Medical Science, the University of Tokyo
- NA/The Cooperative Research Program (Joint Usage/Research Center program) of Institute for Life and Medical Sciences, Kyoto University
- NA/Hokkaido University Biosurface project
- NA/The Naito Foundation
- NA/Takeda Science Foundation
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous